Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2012/01/002358
CTRI/2012/01/002358
Completed
Phase 2

A prospective phase II study to assess the feasibility, efficacy and tolerance of neoadjuvant Chemotherapy with ultra fractionated radiotherapy prior to definitive chemoradiation in stage IIB, IIIA and IIIB Squamous cell carcinoma of cervix - LDRTCX

Fluid Research Grant CMC Vellore0 sites20 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsHealth Condition 1: null- Women with histologically proven diagnosis of squamous cell carcinoma cervix FIGO stage IIB to IIIB will be included in the study.

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Health Condition 1: null- Women with histologically proven diagnosis of squamous cell carcinoma cervix FIGO stage IIB to IIIB will be included in the study.
Sponsor
Fluid Research Grant CMC Vellore
Enrollment
20
Status
Completed
Last Updated
4 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
Fluid Research Grant CMC Vellore

Eligibility Criteria

Inclusion Criteria

  • •a.Inclusion Criteria:
  • •Women with histologically proven diagnosis of squamous cell carcinoma cervix FIGO stage IIB to IIIB will be included in the study. Inclusion criteria
  • •1\.Age less than or equal to 70 years
  • •2\.ECOG less than or equal to 2
  • •3\.Pretreatment Hb more than 9 gm%
  • •4\.Leucocytes more than or equal to 4000 / mm3
  • •5\.Platelets more than or equal to 1,00,000/mm3
  • •6\.Normal hepatic and renal parameters

Exclusion Criteria

  • •Patients with renal, hepatic or cardiac co\-morbidities or previous history of chemotherapy/radiation therapy/malignancy will be excluded

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Not Applicable
Clinical study to determine the appropriateness of a starting dose of 160 mg/day of lazertinib in patients with EGFR T790M-positive non-small cell lung cancerNeoplasms
KCT0008332Samsung Medical Center117
Active, not recruiting
Phase 1
A phase II study evaluating the feasibility and clinical efficacy of atezolizumab consolidation treatment in high risk diffuse large B-cell lymphoma.
EUCTR2017-002605-35-BEHOVON Foundation109
Active, not recruiting
Phase 1
A phase II study evaluating the feasibility and clinical efficacy of atezolizumab consolidation treatment in high risk diffuse large B-cell lymphoma.
EUCTR2017-002605-35-NLHOVON Foundation109
Recruiting
Phase 2
A phase II study evaluating the feasibility and clinical efficacy of atezolizumab consolidation treatment in high risk diffuse large B-cell lymphomaDiffuse large B-cell lymphomalymphoma10025320
NL-OMON52540HOVO90
Active, not recruiting
Phase 1
Clinical trial to evaluate the efficacy and the safety of a combination of bendamustine-melphalan as preparative regimen to autologous transplantation of hematopoietic cells for multiple myeloma who did not responded after previous high-dose therapyMultiple myelomaTherapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
EUCTR2014-000130-37-ITFONDAZIONE NEOPLASIE SANGUE ONLUS (FO.NE.SA. Onlus)73